What's Happening?
BridgeBio Pharma's protein stabilizing therapy, Attruby, has demonstrated kidney-protective effects in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). A posthoc analysis of data from a Phase 2 study and the Phase 3 ATTRibute-CM trial
revealed that patients on Attruby experienced significant improvements in kidney function, as measured by the estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio. These findings suggest that Attruby offers distinct cardiorenal protective benefits compared to other therapies in the market. Analysts from Jefferies have noted that these results could differentiate Attruby in the competitive ATTR-CM space.
Why It's Important?
The kidney-protective effects of Attruby are significant as they offer a potential advantage over existing treatments for ATTR-CM, a condition with limited therapeutic options. By preserving kidney function, Attruby could improve patient outcomes, reduce hospitalizations, and potentially lower mortality rates. This differentiation could enhance BridgeBio's competitive position in the ATTR-CM market, which includes established players like Pfizer's Vyndaqel/Vyndamax. The positive posthoc analysis may also bolster investor confidence and support further development and commercialization efforts for Attruby.
What's Next?
BridgeBio is expected to continue its efforts to expand the clinical applications of Attruby, potentially exploring additional indications or combination therapies. The company may also seek regulatory approvals in new markets, leveraging the positive kidney function data to strengthen its case. As the ATTR-CM market evolves, BridgeBio will likely face competition from other companies developing similar therapies, such as AstraZeneca and Ionis. The ongoing development and potential approval of these competing therapies will be closely monitored by industry stakeholders.
